Abstract: Terbium-149 is among the most interesting therapeutic nuclides for medical applications. It decays by emission of short-range α-particles (E α = 3.967 MeV) with a half-life of 4.12 h. The goal of this study was to investigate the anticancer efficacy of a 149 Tb-labeled DOTA-folate conjugate (cm09) using folate receptor ( 
Introduction
Targeted radionuclide therapy using β − -particle-emitting radionuclides (e.g., 131 I, 90 Y, 177 Lu) of variable energies is employed in clinical routine. For this purpose a variety of tumor-targeted biomolecules have been used, ranging from small-molecular weight compounds (e.g., 131 I-MIBG), to peptides (e.g., 177 Lu-DOTATATE) and monoclonal antibodies ( 90 Y-Ibritumomab, Zevalin ® ) [1, 2] . A promising option for a potential improvement of the therapeutic efficacy of radioendotherapy may be the selection of appropriate radionuclides. α-Particles of medically interesting radionuclides provide a 200-to 1,000-fold higher linear energy transfer (LET) than β − -particles [3, 4] . Therefore, and because of the much shorter path-length (25-100 μm) of α-particles compared to β − -particles (0.05-12 mm), α-particle-emitting nuclides may be interesting for targeted radionuclide therapy of micrometastases or even single cancer cells.
Allen et al. suggested the radiolanthanide 149 Tb as the preferred radionuclide for α-radionuclide therapy [3] . A decay scheme with a list of significant emitted radiation of 149 Tb and its daughter nuclides has been previously published by Beyer et al. [5] . 149 Tb decays with a half-life of 4.12 h by emission of short-range α-particles (E α = 3.967 MeV, I = 16.7%) [4, 5] . In addition, it emits γ-rays of an energy (E γ = 165 keV, 26.4%) potentially suitable for single photon emission computed tomography (SPECT) and positrons (E β+ average = 638 keV, 3.8%) which may be detected via positron emission tomography (PET) ( Figure 1A ) [4, 6] . However, there also exists suitable diagnostic matched nuclides such as 155 Tb (T 1/2 = 5.32 d, E γ = 87 keV, I = 32% and 105 keV, I = 25%) and 152 Tb (T 1/2 = 17.5 h, E β+ average = 1.08 MeV, I = 17%) for imaging purposes via SPECT and PET, respectively [7] . Tb can be stably coordinated by macrocyclic chelators (e.g., DOTA) as it has been recently demonstrated using the β − -emitting nuclide 161 Tb [7] [8] [9] 212 Bi from the DOTA complex [12] . In such cases the decay of the daughter nuclides may occur in non-targeted organs which could cause undesired toxicity to healthy tissue [13] . In spite of the fact that the α-emitting 211 At (T 1/2 = 7.21 h) is considered appropriate for medical use with regard to the physical properties, a major impediment to practical applications is the low in vivo stability of astatine bonds with aromatic carbon bonds [14] . However, current availability of 149 Tb is poor due to production routes which are not easily accessible [6] . Potential production routes include irradiation of rare 152 Gd targets with high energy protons (>50 MeV) or the use of light ions as projectiles of >500 MeV protons for spallation reactions. However, in both cases mass separation is required to avoid radioisotopic impurities. The aim of the present study was to complement our preliminary in vivo results [7] by a further study using 149 Tb for in vitro cell viability assays and in vivo using a well-established tumor mouse model. We employed the recently developed DOTA-folate conjugate (herein referred to as cm09, Figure 1B ) and human KB cancer cells which express the folate receptor (FR) at high levels. From our previous in vivo studies performed with 177 Lu-cm09, it is known that the novel folate radioconjugate is applicable for preclinical therapy studies in the KB tumor mouse model where it provides an excellent tumor accumulation of radioactivity and as a consequence high antitumor efficacy [15] .
Experimental

Chemicals and Reagents for Production and Purification of 149 Tb
Gold foils (thickness: 0.1 mm, purity: 99.95%, Goodfellow Cambridge Ltd. Huntingdon, UK) were electrolytically coated with a thin layer of zinc (purity ≥99.9%). The acids in this work (HNO 3 suprapur and HCl suprapur) were obtained from VWR International GmbH (Dietikon, Switzerland) and diluted with MilliQ water (18.2 MΩ· cm; Millipore AG, Zug, Switzerland). A solution of NH 3 (25%, suprapur) was obtained from VWR International GmbH. α-Hydroxyisobutyric acid (α-HIBA, purity: 99%), L-lactic acid (C 3 H 6 O 3 , purity ≥99%) and NaOH monohydrate (Traceselect, purity ≥99.9995%) were obtained from Sigma-Aldrich International GmbH (St. Gallen, Switzerland).
Production of 149 Tb
149 Tb was produced at the isotope separation online facility ISOLDE (CERN, Geneva, Switzerland)
as previously reported [7, 16, 17] . In brief, a tantalum target (50 g/cm 2 ) was irradiated with high-energy (~1.4 GeV) protons. After effusion of the spallation products from the heated target (~2,000 °C) they were ionized by surface ionization and resonant laser ionization. The monocations were extracted from the ion source, accelerated to 50 keV and separated in a magnetic field according to their mass [16, 17] . Products of mass number 149 were implanted into a zinc-coated gold foil (70 mm 2 ) and shipped to PSI for the purification procedure.
Purification of 149 Tb
The zinc layer was dissolved in a solution mixture of HNO 3 /NH 4 NO 3 (0.2 M NO 3 − , pH 1, 500 μL) at 50 °C. Isolation of 149 Tb from isobar and pseudo-isobar impurities and stable Zn was accomplished by cation exchange chromatography. For this purpose a column (5 mm × 35 mm) filled with a strongly acidic macroporous cation exchange resin was employed as recently reported [7, 18] . 149 Tb and 149 Gd were eluted with α-HIBA (0.13 M) at a flow rate of 0.33 mL/min allowing their separation [7] . Further radioactive impurities and stable Zn remained on the column. Regeneration of the column was carried out using higher concentrated α-HIBA ( 
Preparation of 149 Tb-cm09 and Stability in Blood Plasma
Radiolabeling was performed by addition of 18 μL of the DOTA-folate (cm09) stock solution (10 mM, corresp. to 18 nmol of cm09) to the obtained solution of 149 Tb (25 MBq) in L-lactate (pH 4.7). The reaction mixture was incubated for 10 min at 95 °C. Quality control was performed by HPLC using a C-18 reversed phase column (Xterra MS C-18, 5 μm, 15 cm × 4.6 cm, Waters, Milford, MA, USA). The mobile phase consisted of MilliQ water with 0.1% trifluoroacetic acid (A) and methanol (B) with a linear gradient from 5% to 80% B over 25 min at a flow rate of 1 mL/min. The product (R t = 19.5 min) was obtained with a radiochemical purity of >96%. After addition of Na-DTPA (10 μL, 5 mM, pH 5) the labeling solution (1.0-1.2 MBq/nmol) was directly used for in vitro and in vivo application. The stability of 149 Tb-cm09 was investigated by incubation of the radioconjugate (50 μL, ~1 MBq) in human plasma (250 μL) at 37 °C. Aliquots (50 μL) were taken for analysis after 30 min, 1 h and 4 h. The proteins were precipitated by addition of methanol (200 μL) and the supernatants were analyzed using HPLC.
Cell Culture
KB cells (human cervical carcinoma cell line, HeLa subclone; ACC-136) were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). Cells were cultured as monolayers at 37 °C in a humidified atmosphere containing 5% CO 2 . Importantly KB cells were cultured in a folate-free special cell culture medium, FFRPMI (modified RPMI, without folic acid, vitamin B 12 and phenol red; Cell Culture Technologies GmbH, Gravesano/Lugano, Switzerland). FFRPMI media was supplemented with 10% heat-inactivated fetal calf serum (FCS), L-glutamine and antibiotics (penicillin/streptomycin/fungizone). Routine culture treatment was performed twice a week.
In Vitro Cell Viability Studies
Inhibition of KB cell viability was investigated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [19] . The cells were harvested and seeded in 96-well plates at 2.5 × 10 3 cells per well in a final volume of 200 μL FFRPMI medium with supplements. After 24 h incubation for cell adhesion, the medium was removed and the cells were incubated with 149 Tb-cm09 (0.05-500 kBq in 200 μL medium/well) alone or in combination with excess folic acid (200 nM) for 4 h at 37 °C. Cell incubation with FFRPMI medium only was performed as a control experiment. After incubation, the supernatants were removed and KB cells were washed with PBS (200 μL/well) before addition of supplemented FFRPMI medium (200 μL/well). Cells were then allowed to grow for 4 days before analysis as previously reported [20] . After addition of 30 μL of an MTT solution (5 mg/mL) to each well, the well-plates were incubated for an additional 4 h at 37 °C. The medium was removed and the dark-violet formazan crystals were dissolved in dimethyl sulfoxide. The absorbance was determined at 560 nm using a microplate reader (Victor X3, Perkin Elmer, Waltham, MA, USA). To quantify cell viability, the ratio of the absorbance of the test samples to the absorbance of control cell samples (=100% viability) was calculated using Microsoft Excel software (Microsoft Corp. Redmond, WA, USA).
In Vivo Therapy Studies
In vivo experiments were approved by the local veterinary department and conducted in accordance with the Swiss law of animal protection. Four to five-week-old female, athymic nude mice (CD-1 Foxn-1/nu) were purchased from Charles River Laboratories (Sulzfeld, Germany). They were fed with a folate-deficient rodent diet (ssniff Spezialdiä ten GmbH, Soest, Germany) starting 5 days prior to tumor cell inoculation [21] . Endpoint criteria were defined as weight loss of >15% of the initial body weight (at day 0), tumor volume >1,000 mm 3 , ulceration or bleeding of the tumor xenograft or abnormal behavior indicating pain or unease of the animal. The therapy study was performed according to the injection protocol shown in Table 1 . Twelve mice were subcutaneously inoculated with 5 × 10 6 KB tumor cells (suspended in 100 μL PBS) as previously reported 4 days before injection of the radioactive folate conjugate [15] . Mice were removed from the study if one or several of the predefined endpoint criteria were reached which required euthanasia. The therapeutic efficacy was expressed as the percentage of tumor growth inhibition (%TGI) calculated according to the formula: %TGI = 100 − (RTV T /RTV U × 100), where RTV T is the mean relative tumor volume of treated mice (groups B or C), and RTV U is the mean relative tumor volume of untreated mice (group A) determined at day 21 when the first control mouse was euthanized. The tumor growth delay index (TGDI) was calculated according to the formula: TGDI = TGD T /TGD U . It was defined as the mean tumor growth delay ratio of treated (TGD T ) and untreated animals (TGD U ) which was required to increase the RTV 5-fold [22] .
Determination of Plasma Parameters
Plasma parameters such as blood urea nitrogen (BUN), alkaline phosphatase (ALP), and total bilirubin (TBIL) were measured from all mice at day 14 after start of the therapy and before euthanasia of each mouse. BUN is a common parameter to determine potential damage to the kidneys whereas increased ALP and TBIL could be an indication for impaired liver function. Plasma samples were prepared by centrifugation of blood samples (150-200 μL per mouse) drawn from the sublingual vein of each mouse and collected in heparinized vials (Microvette, 200 mL Sarstedt, Nümbrecht, Germany). For each parameter a plasma volume of 10 μL was required for the analysis using a Fuji Dri-Chem 40000i analyzer (Polymed Medical Center AG, Glattbrugg, Switzerland).
Dosimetric Calculations
To estimate the equivalent absorbed dose for 149 Tb-cm09 in KB tumor xenografts, biodistribution data obtained with 161 Tb-cm09 were used. Based on these data the following calculations were made:
(i) the cumulative radioactivity was calculated from integrated AUCs (MBq· s) of biodistribution data expressed in non decay-corrected percent injected activity [%IA] per tumor mass (assumed as 100 mg, due to an approximate calculated volume of the tumors at the start of the therapy); (ii) the adsorbed radiation dose in tumor xenografts was assessed for a sphere of 100 mg using the Unit Density Sphere Model from RADAR [23] ; (iii) The absorbed dose (mGy/MBq) was calculated by multiplying the AUC (s; normalized to 1 MBq ID) with the S-value (mGy/MBq· s); and (iv) the dose (mGy) was calculated by multiplying the absorbed dose (mGy/MBq) with the amount of injected radioactivity.
Statistical Significance
Significance of the survival time and tumor growth delay was calculated by the performance of the t-test (Microsoft Excel). All analyses were two-tailed and considered as type 3 (two sample unequal variance). A p-value < 0.05 was considered statistically significant. Tb after separation on column I. The total yield of the separation process was ~63% (corresponding to a ~94% decay-corrected yield) and the whole isolation process including measurement of the single elution fractions was accomplished within 145 min. The L-lactate-based physiological formulation was suitable not only for the direct performance of radiolabeling of cm09 but allowed even in vitro and in vivo application without further purification steps. In comparison to our previous study [7] where we used 149 Tb for radiolabeling directly after elution from the first column in the α-HIBA solution (~0.15 M), the purification process was optimized in the present study. The advantages were two-fold: Firstly, using the second chromatographic column allowed concentration of the radioactivity in a smaller volume which was favorable for subsequent radiolabeling steps and in vivo application. Secondly, the elution was carried out with a solution of L-lactate providing 149 Tb in a more physiological solution compared to the α-HIBA solution which was employed in our previous studies.
Results and Discussion
Production and Purification of 149 Tb
Radiosynthesis of 149
Tb-cm09 and Stability in Blood Plasma
Radiolabeling of cm09 (18 nmol) with 149 Tb (25 MBq) resulted in a product peak of the radiolabeled product with a retention time (R t ) of 19.5 min. The chromatogram was equal to what was previously obtained with the 161 Tb-labeled match ( 161 Tb-cm09) [9] . On the other hand injection of free 149/161 Tb(III) was eluted almost with the front (R t = 3 min). These findings confirmed the identity of the product peak as 149 Tb-cm09 which was obtained with a radiochemical purity of >96% with only insignificant traces of free 149 Tb(III).
Incubation of 149
Tb-cm09 (1.0-1.2 MBq/nmol) in blood plasma at 37 °C revealed high stability (>98%) of the folate radioconjguate over at least 4 hours. These findings were expected as it was previously shown that 161 Tb-cm09 was completely stable in human blood plasma over several days [7, 9] .
In Vitro Application of 149 Tb-cm09
In vitro cell viability assays were performed to investigate the effect of 149 Tb-cm09. FR-positive KB tumor cells were incubated with increasing radioactivity concentrations of 149 Tb-cm09. It was found that the viability of the KB cells was inhibited in an activity-dependent manner ( Figure 3 ). Application of a low radioactivity concentration of 149 Tb-cm09 (0.5 kBq/mL) resulted in an only 20%-reduction of the tumor cell viability. However, a 1,000-fold higher radioactivity concentration (500 kBq/mL) resulted in an almost complete loss of KB cell viability. Addition of excess folic acid to block cell surface exposed FRs abolished the effect of 149 Tb-cm09 completely even at high radioactivity concentrations. Under these conditions tumor cells grew normally and comparably to untreated control cells (Figure 3 ). These findings clearly indicated a FR-specific effect of 149 Tb-cm09. (yellow bars). Exposure of cells to unlabeled cm09 (100 nM to 10 μM) had no effect on cell growth (data not shown).
Therapy Study in Tumor-Bearing Mice Using 149 Tb-cm09
The therapy study in KB tumor-bearing nude mice showed significant tumor growth delay (TGD) in 149 Tb-cm09 treated mice compared to untreated control mice ( Figure 4A ). The tumor growth delay index for a 5-fold increased tumor volume compared to the tumor volume at the beginning of the study (TGDI 5 ) reached a value of 1.5 (p = 0.04) for mice of group B which were treated with 2.2 MBq 149 Tb-cm09. This means a 1.5-fold higher value than for untreated control mice (TGDI 5 = 1). In mice of group C, which received 3.0 MBq of 149 Tb-cm09, the TGDI 5 was even 2.0-fold (p = 0.01) increased compared to the TGDI 5 of untreated controls. At day 21 when the first control mouse had to be euthanized due to an oversized tumor the average relative tumor volume (RTV) was significantly smaller in treated mice of group B (p = 0.01) and group C (p = 0.001) compared to the tumor volume of untreated control mice (group A). At this time point of the study tumor growth was inhibited by 62% (group B) and 85% (group C), respectively, indicating a dose-dependent therapeutic efficacy of Analysis of blood plasma parameters (BUN, ALP and TBIL) did not reveal significant changes (p > 0.05) among control mice and mice treated with 149 Tb-cm09 (Table 2 ). This analysis indicated unimpaired renal and hepatobiliar function. Hence, it can be concluded that acute radiotoxic effects to the kidneys and the liver were not experienced by FR-targeted α-radionuclide therapy over the whole time of this study which lasted for 35 days. More detailed studies to investigate effects of 149 Tb-cm09
on kidney function will be necessary since undesired side-effects on the long-term cannot be excluded based on the examinations performed herein. Table 2 . Results of plasma analysis at day 14 and before terminal (in parentheses); (BUN = blood urea nitrogen, ALP = alkaline phosphatase, TBIL = total bilirubin). Overall the present results outperformed our previous data which were obtained upon administration of two injections of 149 Tb-cm09 at low quantities of radioactivity (1.1 MBq and 1.3 MBq, respectively) [7] . Compared to our previous therapy study, the present study design differed in that the mice received the whole amount of radioactivity in a single injection of either 2. Tb-labeled rituximab (5.5 MBq per mouse) was investigated in a leukemia animal model using SCID mice with an intravenous graft of Daudi cells [5] . Their aim was to examine the efficacy of 149 Tb-rituximab to specifically kill circulating single cancer cells or small cell clusters in vivo. The therapy was started within 3 days upon intravenous xenografting of a lethal number of Daudi cells when most of the tumor cells were expected to be still in circulation [5] . Whereas untreated control mice had to be euthanized within the first 37 days a tumor-free survival was found for over 120 d in almost 90% of the 149 Tb-rituximab treated animals.
Since application of the same amount of unlabeled rituximab did not show a therapeutic effect, the
